A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

Healthy Participants Clinical Trial

Official title:

A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Crossover, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of PF-07853578 Administered to Healthy Adult Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05890105
• Other study ID #: C5161001
• Status: Completed
• Phase: Phase 1
• Start date: June 2, 2023
• Est. completion date: December 1, 2023

Study information

• Verified date: December 2023
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purposes of this study are:

• To see how the new medicine (PF-07853578) under study is tolerated. And if there are any important side effects. And, how people feel after taking single increasing amount of the medicine by mouth.

• To measure the amount of study medicine in your blood after the medicine is taken by mouth.

This study is seeking for participants who:

• are females of 18 to 65 years old and are not able to give birth to a child.

• are males of 18 to 65 years old.

• have body mass index of 16 to 31 kilograms per meter squared.

• have a total body weight of more than 50 kilograms (110 pounds). Participants will be randomly selected to receive either study medicine (PF-07853578) or placebo (a pill that has no medicine in it). Participants may receive up to 4 amounts of study medicine and up to 2 amounts of placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: December 1, 2023
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Female participants of non-childbearing potential and male participants aged 18 to 65 years at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.

2. BMI of 16 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion Criteria:

1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

2. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention, with the exception of moderate or strong cytochrome P450 3A (CYP3A) inducers or inhibitors which are prohibited within 14 days plus 5 half-lives prior to the first dose of study intervention.

3. Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.

4. Screening supine blood pressure (BP) =140 mm Hg (systolic) or =90 mm Hg (diastolic) for participants <60 years; and =150/90 mm/Hg for participants =60 years old, following at least 5 minutes of supine rest.

5. Renal impairment as defined by an estimated glomerular filtration rate (eGFR) of <75 mL/min/1.73m².

6. Hematuria as defined by >1+ heme on urine dipstick.

7. Albuminuria as defined by albumin/creatine (Cr) ratio on spot urine albumin (UA) >30 mg/g.

8. Standard 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.

9. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

• Alanine aminotransferase (ALT), aspartate aminotransferase (AST), Bilirubin =1.05×ULN.

• Total cholesterol, triglycerides, or direct LDL =1.25×ULN.

Related Conditions & MeSH terms

• Healthy Participants

Intervention

Drug:
• PF-07853578
PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
• Placebo
Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.

Locations

Country	Name	City	State
United States	New Haven Clinical Research Unit	New Haven	Connecticut
United States	Pfizer Clinical Research Unit - New Haven	New Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) Following Single Ascending Dose		Day 1 to Day 10 in each period
Primary	Number of Participants With Clinical Laboratory Abnormalities		Day 1 to Day 10 in each period
Primary	Number of Participants With Clinically Significant Change From Baseline in Vital Signs		Day 1 to Day 10 in each period
Primary	Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings		Day 1 to Day 10 in each period
Primary	Number of Participants With Clinically-Significant Change From Baseline in Neurological Examination Findings		Day 1 to Day 10 in each period
Primary	Number of Participants With Clinically Significant Change From Baseline in Telemetry Findings		0 to 8 hours post-dose on Day 1 in each period
Primary	Number of Participants With Clinically-Significant Change From Baseline in Physical Examination Findings		Day 1 to Day 10 in each period
Secondary	Maximum Observed Plasma Concentration (Cmax) of PF-07853578		Day 1 0 hour to 72 hours post-dose in each period
Secondary	Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast) of PF-07853578		Day 1 0 hour to 72 hours post-dose in each period
Secondary	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07853578		Day 1 0 hour to 72 hours post-dose in each period
Secondary	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07853578		Day 1 0 hour to 72 hours post-dose in each period
Secondary	Plasma Half-Life (t1/2) of PF-07853578		Day 1 0 hour to 72 hours post-dose in each period

External Links

•   To obtain contact information for a study center near you, click here.